Copper to Zinc Ratio in End Stage Renal Disease Patients Outcome

N/ANot Yet RecruitingNCT07109778

Minia University150 enrolled

Overview

The goal of this observational clinical trial is to Study the impact of copper to zinc ratio on the outcome of ESRD patients

End-stage renal disease (ESRD) carries high morbidity and mortality due to cardiovascular complications, highlighting the need for ongoing research. Trace elements as copper (Cu), and zinc (Zn), are essential for physiological functions, enzyme activity, metabolism, and immune defense. In ESRD patients, Cu and Zn imbalances, with a higher Cu/Zn ratio are linked to greater cardiovascular problems. The relationship between the Cu/Zn ratio and clinical outcomes in ESRD needs more exploration

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

ESRD (End Stage Renal Disease)Control Condition

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * ESRD patients including those on maintenance HD Exclusion Criteria: * Acute kidney injury or rapidly progressive glomerulonephritis, acute infections or active inflammatory conditions as sepsis and autoimmune diseases, liver cirrhosis (Child-Pugh Class B or C), gastrointestinal disorders as inflammatory bowel disease, malabsorption, history of organ transplantation excluding kidney transplantation who may be included in a separate analysis if sufficient numbers are recruited, receiving total parenteral nutrition, Cu or Zn metabolism disorders as Wilson's disease, vitamin complex supplementation or antioxidants within the past 6 months, recent hospitalization within the past 3 months, recent surgery within 3 months, recent blood transfusion \< 3 months, Pregnancy or lactation, Malignancy.

Locations (1)

Nephrology and urology hospital, Minia unersity hospital, Faculty of medicine, Minia university

Minya, Egypt

Outcomes

Primary Outcomes

To determine whether an elevated serum Cu/Zn ratio is associated with an increased risk of cardiac complications in chronic hemodialysis patients.

measuring serum Cu/Zn ratio and determining if it is associated with an increased risk of cardiac complications in chronic hemodialysis patients.

Time frame: 6-8 months

Central Contacts

Kerolles Adel Estawrow Saleh, MBChB

CONTACT

01227657867 Kerolesadel1997@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.